Baxter International Inc. (NYSE:BAX)

Net sales exhibited a consistent upward trajectory from 2011 through 2014, increasing from 13,893 million US$ to 16,671 million US$. However, a significant contraction is observed in 2015, where net sales decreased to 9,968 million US$. This decline is directly attributable to the absence of revenue from the BioScience segment in the final reporting period.

BioScience Segment Performance

The BioScience segment showed steady growth between 2011 and 2014, rising from 6,053 million US$ to 6,699 million US$. This represents a sustained increase in revenue over the four-year period. No revenue is reported for this segment for the period ending December 31, 2015.

Medical Products Segment Performance

The Medical Products segment demonstrated strong growth, particularly between 2012 and 2014. Revenues increased from 7,840 million US$ in 2011 to a peak of 9,972 million US$ in 2014. For the 2015 period, revenue remained nearly flat at 9,968 million US$, indicating a stabilization of growth in this division.

Net Sales Correlation

Between 2011 and 2014, net sales were the aggregate result of both the BioScience and Medical Products segments. In 2015, net sales converged exactly with the Medical Products revenue of 9,968 million US$, confirming that the BioScience segment no longer contributed to the total net sales for that fiscal year.